- Home
- BELFB vs DNTH Comparison
BELFB vs DNTH Comparison
Compare BELFB & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BELFB
- DNTH
- Stock Information
- Founded
- BELFB 1949
- DNTH 2015
- Country
- BELFB United States
- DNTH United States
- Employees
- BELFB N/A
- DNTH 78
- Industry
- BELFB
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- BELFB
- DNTH Health Care
- Exchange
- BELFB Nasdaq
- DNTH Nasdaq
- Market Cap
- BELFB 1.8B
- DNTH 1.5B
- IPO Year
- BELFB N/A
- DNTH N/A
- Fundamental
- Price
- BELFB $150.97
- DNTH $38.87
- Analyst Decision
- BELFB Strong Buy
- DNTH Strong Buy
- Analyst Count
- BELFB 4
- DNTH 10
- Target Price
- BELFB $142.25
- DNTH $66.38
- AVG Volume (30 Days)
- BELFB 114.4K
- DNTH 1.0M
- Earning Date
- BELFB 10-22-2025
- DNTH 11-06-2025
- Dividend Yield
- BELFB 0.19%
- DNTH N/A
- EPS Growth
- BELFB N/A
- DNTH N/A
- EPS
- BELFB 4.05
- DNTH N/A
- Revenue
- BELFB $594,034,000.00
- DNTH $4,854,000.00
- Revenue This Year
- BELFB $25.48
- DNTH N/A
- Revenue Next Year
- BELFB $5.57
- DNTH N/A
- P/E Ratio
- BELFB $37.23
- DNTH N/A
- Revenue Growth
- BELFB 6.08
- DNTH 17.87
- 52 Week Low
- BELFB $58.00
- DNTH $13.37
- 52 Week High
- BELFB $152.45
- DNTH $39.87
- Technical
- Relative Strength Index (RSI)
- BELFB 65.36
- DNTH 84.85
- Support Level
- BELFB $144.42
- DNTH $36.00
- Resistance Level
- BELFB $149.41
- DNTH $24.81
- Average True Range (ATR)
- BELFB 4.64
- DNTH 2.79
- MACD
- BELFB -0.06
- DNTH 0.90
- Stochastic Oscillator
- BELFB 93.37
- DNTH 94.17
About BELFB Bel Fuse Inc. Class B
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.